GO
Loading...

Rivals Gain on Pfizer Drug Trial News

Thursday, 21 Apr 2011 | 5:42 PM ET

I noted on the air this afternoon that Pfizer , which was trading at about $20.20, dropped in a few minutes to about $19.50 on heavy volume.

The European League Against Rheumatism has posted a summary of a trial of Pfizer's rheumatoid arthritis drug Tofacitinib, indicating that four patients died.

Several other health care companies that have competing drugs rose on this news: YMI Biosciences , Abbott Laboratories , and Rigel , which is partnered with AstraZeneca .

More:

  • Deaths in Pfizer Arthritis Trial Hurt Shares

_____________________________
Bookmark CNBC Data Pages:

_____________________________

Want updates whenever a Trader Talk blog is filed? Follow me on Twitter: twitter.com/BobPisani.

Questions? Comments? tradertalk@cnbc.com

  Price   Change %Change
ABT
---
AZN
---
PFE
---
RIGL
---
YM
---

Featured

  • A CNBC reporter since 1990, Bob Pisani covers Wall Street from the floor of the New York Stock Exchange.

Wall Street